Iphigenia L. Koumenis

4.8k total citations · 1 hit paper
12 papers, 2.3k citations indexed

About

Iphigenia L. Koumenis is a scholar working on Molecular Biology, Physiology and Oncology. According to data from OpenAlex, Iphigenia L. Koumenis has authored 12 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Physiology and 3 papers in Oncology. Recurrent topics in Iphigenia L. Koumenis's work include Cell death mechanisms and regulation (3 papers), Delphi Technique in Research (2 papers) and CAR-T cell therapy research (2 papers). Iphigenia L. Koumenis is often cited by papers focused on Cell death mechanisms and regulation (3 papers), Delphi Technique in Research (2 papers) and CAR-T cell therapy research (2 papers). Iphigenia L. Koumenis collaborates with scholars based in United States, Czechia and New Zealand. Iphigenia L. Koumenis's co-authors include Zahra Shahrokh, Laura DeForge, David A. Lawrence, Avi Ashkenazi, Ralph Schwall, Ling Chang, Andrea Hebert, Hartmut Koeppen, Susan W.S. Leung and Jeanine L. Bussiere and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Brain Research.

In The Last Decade

Iphigenia L. Koumenis

12 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Avi Ashkenazi, Sharon Fong et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iphigenia L. Koumenis United States	10	1.9k	669	529	506	251	12	2.3k
Anna Trauzold Germany	32	2.0k 1.1×	844 1.3×	960 1.8×	715 1.4×	298 1.2×	72	2.8k
Eri Oda Japan	13	1.9k 1.0×	616 0.9×	1.2k 2.2×	387 0.8×	324 1.3×	34	2.9k
Gianluca Bossi Italy	30	1.4k 0.7×	254 0.4×	988 1.9×	547 1.1×	209 0.8×	53	2.2k
Miha Pakusch Australia	14	3.1k 1.6×	659 1.0×	640 1.2×	370 0.7×	526 2.1×	19	3.5k
Isabella Manni Italy	25	1.9k 1.0×	279 0.4×	785 1.5×	494 1.0×	123 0.5×	57	2.5k
Yiyu Zou United States	23	2.5k 1.3×	616 0.9×	1.3k 2.4×	666 1.3×	219 0.9×	51	3.6k
Antonis S. Zervos United States	25	2.8k 1.5×	392 0.6×	492 0.9×	274 0.5×	379 1.5×	40	3.6k
Kirsteen J. Campbell United Kingdom	25	2.0k 1.0×	561 0.8×	681 1.3×	1.0k 2.1×	163 0.6×	40	2.8k
Rieko Ohki Japan	21	2.3k 1.2×	319 0.5×	1.2k 2.3×	445 0.9×	266 1.1×	50	3.0k
Tongsen Zheng China	30	1.8k 1.0×	688 1.0×	876 1.7×	1.1k 2.2×	220 0.9×	63	3.2k

Countries citing papers authored by Iphigenia L. Koumenis

Since Specialization

Citations

This map shows the geographic impact of Iphigenia L. Koumenis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iphigenia L. Koumenis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iphigenia L. Koumenis more than expected).

Fields of papers citing papers by Iphigenia L. Koumenis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iphigenia L. Koumenis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iphigenia L. Koumenis. The network helps show where Iphigenia L. Koumenis may publish in the future.

Co-authorship network of co-authors of Iphigenia L. Koumenis

This figure shows the co-authorship network connecting the top 25 collaborators of Iphigenia L. Koumenis. A scholar is included among the top collaborators of Iphigenia L. Koumenis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iphigenia L. Koumenis. Iphigenia L. Koumenis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Patel, Krish, Swathi Namburi, Tahir Latif, et al.. (2024). Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.. Journal of Clinical Oncology. 42(16_suppl). 7023–7023. 8 indexed citations

Patel, Krish, Sarah M. Rothman, Stephanie S. Yee, et al.. (2023). The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.. Journal of Clinical Oncology. 41(16_suppl). TPS7580–TPS7580. 3 indexed citations

Ravandi, Farhad, Iphigenia L. Koumenis, A. Johri, et al.. (2019). Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 105(6). 1567–1574. 30 indexed citations

Verstovšek, Srđan, Ruben A. Mesa, Jason Gotlib, et al.. (2011). Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).. Journal of Clinical Oncology. 29(15_suppl). 6500–6500. 25 indexed citations

Surette, Marc E., Iphigenia L. Koumenis, Michelle B. Edens, et al.. (2003). Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: A randomized, placebo-controlled, parallel-group, prospective trial. Clinical Therapeutics. 25(3). 972–979. 30 indexed citations

Surette, Marc E., Iphigenia L. Koumenis, Michelle B. Edens, Kenneth M. Tramposch, & Floyd H. Chilton. (2003). Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clinical Therapeutics. 25(3). 948–971. 41 indexed citations

Koumenis, Iphigenia L., et al.. (2000). Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)2 by amine-specific PEGylation with preserved bioactivity. International Journal of Pharmaceutics. 198(1). 83–95. 44 indexed citations

Xu, Lijun, Iphigenia L. Koumenis, Jonathan L. Tilly, & Rona G. Giffard. (1999). Overexpression of bcl-xLProtects Astrocytes from Glucose Deprivation and Is Associated with Higher Glutathione, Ferritin, and Iron Levels . Anesthesiology. 91(4). 1036–1036. 43 indexed citations

Ashkenazi, Avi, Sharon Fong, Susan W.S. Leung, et al.. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation. 104(2). 155–162. 1892 indexed citations breakdown →

10.

Papadopoulos, Marios C., Iphigenia L. Koumenis, Lijun Xu, & Rona G. Giffard. (1998). Potentiation of murine astrocyte antioxidant defence by bcl‐2: protection in part reflects elevated glutathione levels. European Journal of Neuroscience. 10(4). 1252–1260. 60 indexed citations

11.

Papadopoulos, Marios C., Iphigenia L. Koumenis, Laura L. Dugan, & Rona G. Giffard. (1997). Vulnerability to glucose deprivation injury correlates with glutathione levels in astrocytes. Brain Research. 748(1-2). 151–156. 89 indexed citations

12.

Papadopoulos, Marios C., et al.. (1997). Increasing vulnerability of astrocytes to oxidative injury with age despite constant antioxidant defenses. Neuroscience. 82(3). 915–925. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact